YU-YUN SHAOHuang C.-C.Lin S.-D.CHIH-HUNG HSUANN-LII CHENG2020-04-102020-04-1020121078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863940804&doi=10.1158%2f1078-0432.CCR-11-2853&partnerID=40&md5=b4be020f6c5414ebd80aeb933ed970c8https://scholars.lib.ntu.edu.tw/handle/123456789/484101Purpose: Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulinlike growth factor (IGF)-1 levels. We evaluated whether IGF-1 levels were associated with the outcomes of patients with advanced HCC treated with systemic antiangiogenic therapy. Experimental Design: The study was based on patients with advanced HCC who were enrolled in two clinical trials evaluating first-line combination antiangiogenic therapy. Serum samples were collected before treatment and four to six weeks after the start of treatment. The levels of IGF-1, IGF-2, and IGF-binding protein-3 (IGFBP3) were analyzed for their associations with treatment outcomes. Results: A total of 83 patients were included in the study. Patients who had high (?the median level) baseline IGF-1 levels had significantly higher disease control rate (DCR) than patients who had low (<the median level) levels (71% vs. 39%, P = 0.003). The levels of posttreatment IGF-1, and pre- or posttreatment IGF-2 and IGFBP3 were not associated with DCR. Patients with high baseline IGF-1 levels, compared with patients with low levels, had significantly longer progression-free survival (PFS; median, 4.3 vs. 1.9 months, P = 0.014) and overall survival (OS; median, 10.7 vs. 3.9 months, P = 0.009). The high baseline IGF-1 level remains an independent factor associated with favorable PFS and OS in multivariate analysis. Conclusions: High pretreatment IGF-1 levels were associated with better DCR, PFS, and OS of patients who received antiangiogenic therapy for advanced HCC. This finding warrants validation in large studies. ?2012 AACR.[SDGs]SDG3bevacizumab; capecitabine; somatomedin B; somatomedin binding protein 3; somatomedin C; sorafenib; UFT; adult; advanced cancer; aged; antiangiogenic therapy; article; blood sampling; cancer control; cancer prognosis; female; human; liver cell carcinoma; major clinical study; male; metronomic drug administration; outcome assessment; overall survival; phase 2 clinical trial (topic); priority journal; progression free survival; protein analysis; protein blood level; survival time; treatment duration; treatment response; Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Tegafur; Treatment Outcomejournal article10.1158/1078-0432.CCR-11-2853226237322-s2.0-84863940804